-transparent.png){kind=logo}
The survival of host cells following high-dose cytotoxic therapy and allogeneic marrow transplantation has been established previously, but the identity of these cells has not been elucidated in detail. Four patients who received sex-mismatched marrow have been studied for up to 12 months post-transplant using a simultaneous immunophenotyping/fluorescence in situ hybridization technique. The results demonstrate residual host T cells (CD3+), B cells (CD22+) and myeloid cells (CD11c+ and CD13+), and additionally cells of progenitor cell phenotype (CD34+). The long-term persistence of host haemopoiesis may have major relevance to the post-transplant complications of marrow rejection, graft-versus-host disease, and malignant relapse.
C M Price, and
S M Colman, and
E J Kanfer
January 1987,
Nature,
C M Price, and
S M Colman, and
E J Kanfer
October 1992,
Current opinion in immunology,
C M Price, and
S M Colman, and
E J Kanfer
December 1984,
Japanese journal of clinical oncology,
C M Price, and
S M Colman, and
E J Kanfer
June 1985,
British journal of haematology,
C M Price, and
S M Colman, and
E J Kanfer
July 1986,
Nederlands tijdschrift voor geneeskunde,
C M Price, and
S M Colman, and
E J Kanfer
June 1985,
The Tokai journal of experimental and clinical medicine,
C M Price, and
S M Colman, and
E J Kanfer
September 1992,
Bone marrow transplantation,
C M Price, and
S M Colman, and
E J Kanfer
March 1978,
Transplantation proceedings,
C M Price, and
S M Colman, and
E J Kanfer
October 1991,
American journal of hematology,
C M Price, and
S M Colman, and
E J Kanfer
June 1990,
Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen,
